Biotech Values

[dav1234]

Akorn to buy Hi-Tech Pharmacal for $640M
Akorn (AKRX) has agreed to pay $640M to acquire Hi-Tech Pharmacal (HITK), which specializes in difficult-to-manufacture liquid and semi-solid dosage forms of drugs. The offer of $43.50 a share represents a premium of 23.5% to Hi-Tech's closing price of $35.21 yesterday. The combined company is expected to generate annual revenues of over $500M, with the deal expected to add to Akorn's adjusted EPS immediately after closing. The company expects to achieve $15-20M in annual run-rate synergies within 12 months after that. Hi-Tech provides oral solutions and suspensions, topical ointments and creams, nasal sprays, otics, sterile ophthalmics, and sterile ointment and gels. Hi-Tech's shares are suspended until 7:30 ET, while those of Akorn are +0.7%

http://seekingalpha.com/news-article/7428182-akorn-to-acquire-hi-tech-pharmacal-for-640-million